| HOME >> MEDICINE >> TECHNOLOGY |
SAN MATEO, CA — April 27, 2007 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the following abstracts have been accepted for the Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois on June 1-5, 2007:
ZADAXIN® (thymalfasin, thymosin alpha 1) Poster
Presentation
A large first-line, randomized, dose-finding, phase II study on
Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with or without
Interferon alpha (IFN?) vs DTIC plus IFN? in stage IV melanoma.
Tumor response and survival results
(ASCO abstract number: 31541)
SCV-07 Abstract Proceedings
Effect of the Immune Modulating Peptide, SCV-07, in the Murine B16
Melanoma Model
(ASCO abstract number: 35151)
For further information about this conference, please visit www.asco.org.
About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in
the development of therapeutics to treat life-threatening diseases.
SciClone's lead product ZADAXIN® is currently being evaluated
in late-stage clinical trials for the treatment of malignant
melanoma and hepatitis C. ZADAXIN is approved for sale in select
markets internationally, most notably in China where SciClone has
an established sales and marketing operation. A key part of
SciClone's strategy is to leverage its advantage in the rapidly
growing Chinese market by in-licensing or acquiring the marketing
rights to other products, such as DC BeadTM, currently pending
Chinese regulatory approval for the treatment of liver cancer. For
the U.S. market, SciClone's clinical-stage drug development
candidates are SCV-07 for the treatment of viral infectious
diseases and RP101 for the treatment of pancreatic cancer. For more
information about SciClone, visit www.sciclone.com.
The information in the abstracts may contain forward-looking statements including our expectations and beliefs regarding progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended," “suggested” and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including the progress or failure of clinical trials, unanticipated delays or additional expenses incurred during our clinical trials, delays in analyzing and synthesizing data obtained from clinical trials and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.
Corporate Contact
Richard A. Waldron
Executive Vice President and Chief Financial Officer
SciClone Pharmaceuticals, Inc.
650-358-3437
'"/>
Related medicine technology :
1. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |